• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名慢性偏头痛患者使用erenumab后出现雷诺现象。

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine.

作者信息

Manickam Agaath Hedina, Buture Alina, Tomkins Esther, Ruttledge Martin

机构信息

Department of Human Genetics and Molecular Biology Bharathiar University Coimbatore India.

Mater Misericordiae University Hospital Dublin Ireland.

出版信息

Clin Case Rep. 2021 Aug 16;9(8):e04625. doi: 10.1002/ccr3.4625. eCollection 2021 Aug.

DOI:10.1002/ccr3.4625
PMID:34430000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8365535/
Abstract

Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.

摘要

雷诺现象是降钙素基因相关肽（CGRP）单克隆抗体的一种罕见副作用。这些分子疗法是一类相对新型的预防偏头痛药物。未来我们可能会更频繁地看到这种副作用。有雷诺现象病史的患者如果开始使用这些疗法，其症状可能会加重。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0ee/8365535/0b57a0b91c08/CCR3-9-e04625-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0ee/8365535/0b57a0b91c08/CCR3-9-e04625-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0ee/8365535/0b57a0b91c08/CCR3-9-e04625-g001.jpg

相似文献

1
Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine.一名慢性偏头痛患者使用erenumab后出现雷诺现象。
Clin Case Rep. 2021 Aug 16;9(8):e04625. doi: 10.1002/ccr3.4625. eCollection 2021 Aug.
2
Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.降钙素基因相关肽靶向药物与雷诺现象：来自世卫组织药物警戒数据库的真实世界潜在安全性信号。
J Headache Pain. 2022 May 3;23(1):53. doi: 10.1186/s10194-022-01424-w.
3
Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists.降钙素基因相关肽单克隆抗体拮抗剂相关雷诺现象。
Headache. 2019 Sep;59(8):1360-1364. doi: 10.1111/head.13596. Epub 2019 Jul 16.
4
Does prevalence of migraine and Raynaud's phenomenon also increase in Korean patients with proven variant angina?在确诊为变异型心绞痛的韩国患者中，偏头痛和雷诺现象的患病率也会增加吗？
Int J Cardiol. 1995 Aug;51(1):37-46. doi: 10.1016/0167-5273(95)02371-3.
5
Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.与降钙素基因相关肽受体拮抗剂相关的雷诺现象病例报告。
Headache. 2022 Nov;62(10):1419-1423. doi: 10.1111/head.14417. Epub 2022 Nov 25.
6
Association between Raynaud's phenomenon and migraine in a random population of hospital employees.医院员工随机人群中雷诺现象与偏头痛之间的关联。
J Rheumatol. 1993 Jul;20(7):1187-8.
7
Calcium channel blockers for primary and secondary Raynaud's phenomenon.用于原发性和继发性雷诺现象的钙通道阻滞剂。
Cochrane Database Syst Rev. 2017 Dec 13;12(12):CD000467. doi: 10.1002/14651858.CD000467.pub2.
8
Raynaud's phenomenon.雷诺现象
Curr Opin Rheumatol. 1992 Dec;4(6):825-36.
9
Raynaud's phenomenon.雷诺现象
Curr Opin Rheumatol. 1993 Nov;5(6):773-84. doi: 10.1097/00002281-199305060-00013.
10
The role of erenumab in the treatment of migraine.erenumab在偏头痛治疗中的作用。
Ther Adv Neurol Disord. 2020 May 27;13:1756286420927119. doi: 10.1177/1756286420927119. eCollection 2020.

引用本文的文献

1
Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab.偏头痛预防性单克隆抗体的上市后安全性：基于EudraVigilance数据库对eptinezumab、fremanezumab、galcanezumab和erenumab的分析。
Headache. 2025 Jul-Aug;65(7):1080-1094. doi: 10.1111/head.14962. Epub 2025 May 29.
2
Disproportionality analysis of Raynaud's phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system.使用美国食品药品监督管理局不良事件报告系统对与降钙素基因相关肽抑制剂相关的雷诺现象进行不成比例分析。
Sci Rep. 2025 Feb 15;15(1):5675. doi: 10.1038/s41598-025-87421-w.
3

本文引用的文献

1
Raynaud's phenomenon.雷诺现象。
Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101474. doi: 10.1016/j.berh.2019.101474. Epub 2020 Jan 29.
2
Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists.降钙素基因相关肽单克隆抗体拮抗剂相关雷诺现象。
Headache. 2019 Sep;59(8):1360-1364. doi: 10.1111/head.13596. Epub 2019 Jul 16.
3
Innovations in the Assessment of Primary and Secondary Raynaud's Phenomenon.原发性和继发性雷诺现象评估的创新进展
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine.
抗降钙素基因相关肽单克隆抗体在老年偏头痛患者或残疾成年偏头痛患者中的心血管安全性。
JAMA Neurol. 2025 Feb 1;82(2):132-141. doi: 10.1001/jamaneurol.2024.4537.
4
Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system.四种用于预防偏头痛的抗降钙素基因相关肽单克隆抗体的不良事件报告：一项基于美国食品药品监督管理局不良事件报告系统的真实世界研究。
Front Pharmacol. 2024 Jan 9;14:1257282. doi: 10.3389/fphar.2023.1257282. eCollection 2023.
5
Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE.阿联酋基于共识的降钙素基因相关肽（CGRP）类疗法用于偏头痛预防的推荐意见
Neurol Ther. 2023 Dec;12(6):1845-1865. doi: 10.1007/s40120-023-00550-0. Epub 2023 Oct 4.
6
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond.降钙素基因相关肽的生理学、药理学和治疗靶点：偏头痛及其他。
Physiol Rev. 2023 Apr 1;103(2):1565-1644. doi: 10.1152/physrev.00059.2021. Epub 2022 Dec 1.
7
Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline.药物过度使用（MO）及药物过度使用性头痛（MOH）管理S1指南。
Neurol Res Pract. 2022 Aug 29;4(1):37. doi: 10.1186/s42466-022-00200-0.
8
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.欧洲头痛联合会关于使用靶向降钙素基因相关肽通路的单克隆抗体预防偏头痛的指南-2022 更新版。
J Headache Pain. 2022 Jun 11;23(1):67. doi: 10.1186/s10194-022-01431-x.
9
Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.降钙素基因相关肽靶向药物与雷诺现象：来自世卫组织药物警戒数据库的真实世界潜在安全性信号。
J Headache Pain. 2022 May 3;23(1):53. doi: 10.1186/s10194-022-01424-w.
Front Pharmacol. 2019 Apr 16;10:360. doi: 10.3389/fphar.2019.00360. eCollection 2019.
4
CGRP as the target of new migraine therapies - successful translation from bench to clinic.降钙素基因相关肽（CGRP）作为新型偏头痛治疗靶点——从实验室到临床的成功转化。
Nat Rev Neurol. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1.
5
Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study.慢性偏头痛的患病率、残疾程度和社会人口学因素：来自美国偏头痛患病率和预防研究的结果。
Headache. 2012 Nov-Dec;52(10):1456-70. doi: 10.1111/j.1526-4610.2012.02223.x. Epub 2012 Jul 25.
6
Calcitonin gene-related peptide (CGRP) and migraine.降钙素基因相关肽（CGRP）与偏头痛
Headache. 2006 Jun;46 Suppl 1(Suppl 1):S3-8. doi: 10.1111/j.1526-4610.2006.00483.x.
7
CGRP-receptor antagonists--a fresh approach to migraine therapy?降钙素基因相关肽受体拮抗剂——偏头痛治疗的新方法？
N Engl J Med. 2004 Mar 11;350(11):1073-5. doi: 10.1056/NEJMp048016.